Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (6): 889-896    DOI: 10.31083/j.ejgo.2020.06.2239
Systematic Review Previous articles | Next articles
Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature
Francesco Plotti1, *(), Bartolone Martina1, Terranova Corrado1, Luvero Daniela1, Scaletta Giuseppe2, Gatti Alessandra1, Benedetti Panici Pierluigi3, Angioli Roberto1
1Department of Obstetrics and Gynaecology, University of Rome "Campus Bio-Medico", Via Alvaro del Portillo, 200-00128, Rome, Italy
2Unit of Gynecologic Oncology Unit, Department of Women's and Children's Health, A, Gemelli University Polyclinic Foundation, 8-00168, Rome, Italy
3Department of Gynecology Obstetrics and Urology, Policlinico Umberto I, "Sapienza" University of Rome, 5-00185, Rome, Italy
Download:  PDF(252KB)  ( 95 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Although epithelial ovarian cancer (EOC) treatment has greatly improved over the last three decades, a fraction of patients (40-60%) with advanced-stage disease fail to completely respond to standard therapy, because of chemo-resistance to platinum. For this reason, new predictive and monitoring tools were studied to identify platinum resistant EOC patients, with the purpose of improving and personalizing the treatment. In this review, we aim to discuss the latest evidence reported in the literature about the use of Human Epididymis 4 (HE4) to predict platinum resistance among EOC patients. Methods: A comprehensive search of the literature was conducted using the terms "HE4 epithelial ovarian cancer" and "human epididymis protein 4 epithelial ovarian cancer" and they were combined with the terms "chemotherapy", "platinum" and "response". Results: The search identified twelve papers, from January 1952 to December 2019, in line with eligibility criteria for this systematic review, all of which demonstrated good performance of HE4 in predicting platinum sensitivity or resistance. Conclusions: All the available studies present limited and non-homogeneous data, therefore more studies are needed to validate and reinforce the role of HE4 in predicting the response to platinum based chemotherapy among ovarian cancer patients.
Key words:  Ovarian cancer      HE4      Chemotherapy      Platinum      Markers     
Submitted:  07 September 2020      Accepted:  11 November 2020      Published:  15 December 2020     
*Corresponding Author(s):  FRANCESCO PLOTTI     E-mail:  f.plotti@unicampus.it

Cite this article: 

Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.06.2239     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I6/889

[1] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[2] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[3] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[4] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.
[5] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[6] R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.
[7] Laura Baquedano Mainar,Andrea Espiau Romera, Pluvio Jesús Coronado Martín. HE4 in endometriod and non- endometrioid subtype of endometrial cancer does not mean the same[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1039-1044.
[8] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[9] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[10] Yanan Li, Dongge Wang, Xiaodong Li, Wangchao Zhang, Xianghua Huang, Yibin Liu. Appendix invasion of squamous cell carcinoma arising from ovarian mature cystic teratoma and resistant to combination chemotherapy with docetaxel and oxaliplatin: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 841-844.
[11] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[12] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[13] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[14] Qinglian Ma, Wenjie Yan, Jing Yang, Haiyan Wang, Weixiang Wang, Minghui Dong. Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 769-773.
[15] Joseph J. Noh, Sir-Yeon Hong, Byeong-gie Kim. Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 495-499.
No Suggested Reading articles found!